VISTA aims to reduce the serious health inequities caused by Group A Streptococcus (Strep A). Strep A is a common childhood infection that can lead to severe disease, including rheumatic heart disease (RHD), and is recognised as a global health priority. It is also a major driver of antibiotic use in children.
In Australia, First Nations communities experience the highest burden of Strep A related illness. Developing a safe and effective vaccine offers a practical and impactful way to reduce this impact, lessen the need for antibiotics and improve long-term health outcomes.
We’re tackling the problem of Strep A, one of the top five infectious causes of death and disability worldwide.
VISTA brings together key areas of work across the Strep A vaccine development pathway:
- A First Nations–led strategy to guide the vaccine, developed in partnership with the communities most affected in Australia
- Proof of concept (Phase 2b) to understand how well Strep A pharyngitis vaccines work and how safe they are
- Phase 3 trials and regulatory steps needed to support the future approval of a Strep A vaccine in Australia
- Applying research in high‑burden settings so the vaccine can make the greatest impact where it’s needed most
- Building awareness of Strep A through community‑focused initiatives
- A central immunogenicity laboratory to support trials
Our work is driving progress toward a licensed Strep A pharyngitis vaccine, improved RHD prevention, and a strong pipeline of future Strep A vaccines.